@AlCp, Have you ever once stopped to consider that the results for Vaxinia were, in fact, not excellent?
Regarding this poster presentation in mTNBC; the only patient reported to demonstrate any sort of response in this trial, did so when administered an alternative treatment regime.
https://pubmed.ncbi.nlm.nih.gov/38028143/
Are you suggesting the trial results were so excellent that they canned this mTNBC trial after recruiting only 9 patients out of a planned 79?
https://clinicaltrials.gov/study/NCT05081492?tab=history&a=3&b=8#version-content-panel
Looks like the B Cell platform is not the only asset on the chopping block - IMU will likely be pitching Vaxinia in combo with trastuzumab-deruxtecan.
(20min delay)